Calmark's subsidiary in Hong Kong is now registered
Calmark Sweden AB today announces that the Company's subsidiary in Hong Kong has been registered. Calmark Hongkong Limited is a wholly-owned subsidiary of the Swedish company. The effort to establish a subsidiary in mainland China continues.
As previously disclosed by Calmark Sweden AB, China is a priority market for the Company, and the establishment of a subsidiary and the launch of the COVID-19 product and the Neo products have been initiated through a cooperation with Nordic Match. There are about 33,000 hospitals in China, and the Company estimates the Chinese market for the Neo products alone at 12 million tests annually.
The effort to establish a subsidiary of Calmark Hong Kong Lim in mainland China will now continue; Calmark has decided to locate it in the Greater Bay Area. The process to register the products in China is underway.
"China is an important and very exciting market. They are heavily committed to maternal and child care, and the POC segment is growing rapidly. It is therefore a matter of priority to get up and running in China as soon as possible, and Calmark Hong Kong Limited marks the first stage of that journey. Work now continues to establish the mainland company, register our products and recruit personnel. In addition, we are planning to set up a joint venture with interested investors within China, in order to capitalize the subsidiary for the launch in China and throughout Asia," says Anna Söderlund, CEO of Calmark Sweden and Calmark Hong Kong Lim.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a reader and single-use products. The first tests are being launched in 2020. WHO expects 1.5 billion children to be born worldwide prior to 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer decision-making support, which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.